Analysis of Candida glabrata strains with reduced sensitivity to micafungin in vitro isolated from a patient with persistent candidemia

Japanese Journal of Infectious Diseases

Volumn 63, Issue 5, 2010, Pages 332-337

  Ishikawa, Takahiko ^a,d   Takata, Tohru ^a   Akamatsu, Souichirou ^b   Hatakenaka, Kazuaki ^b   Matsumoto, Satoru ^b   Maki, Katsuyuki ^b   Ikeda, Fumiaki ^b,e   Tamai, Rukako ^a,c   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^d UMEÅ UNIVERSITY   (Sweden)

^e LSI MEDIENCE CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; BIAPENEM; CLINDAMYCIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MEROPENEM; MICAFUNGIN; MICONAZOLE; MINOCYCLINE; PREDNISOLONE; SULTAMICILLIN; VORICONAZOLE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; BROTH DILUTION; CANDIDA GLABRATA; CANDIDEMIA; CARCINOMATOUS PERITONITIS; CASE REPORT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; FEVER; FUNGAL STRAIN; FUNGUS ISOLATION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NAUSEA AND VOMITING; NONHUMAN; PULMONARY CANDIDIASIS; SPUTUM CULTURE; STOMACH JUICE;

AGED; ANIMALS; ANTIFUNGAL AGENTS; BODY TEMPERATURE; CANDIDA GLABRATA; CANDIDEMIA; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FATAL OUTCOME; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; KINETICS; LIPOPEPTIDES; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS;

EID: 77957725065     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wiederhold, N.P. and Lewis, J.S., II. (2007): The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin. Pharmacother., 8, 1155-1166.
2. Tawara, S., Ikeda, F., Maki, K., et al. (2000): In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother., 44, 57-62.
3. Mikamo, H., Sato, Y. and Tamaya, T. (2000): In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother., 46, 485-487.
4. Pfaller, M.A. and Diekema, D.J. (2004): Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect., 10 (Suppl. 1), 11-23.
5. Pfaller, M.A., Boyken, L., Hollis, R.J., et al. (2005): In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol., 43, 5425-5427.
6. Sandven, P., Bevanger, L., Digranes, A., et al. (1998): Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J. Clin. Microbiol., 36, 3455-3459.
7. Trick, W.E., Fridkin, S.K., Edwards, J.R., et al. (2002): Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis., 35, 627-630.
8. Voss, A., Kluytmans, J.A., Koeleman, J.G., et al. (1996): Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur. J. Clin. Microbiol. Infect. Dis., 15, 909-912.
9. van Burik, J.A., Ratanatharathorn, V., Stepan, D.E., et al. (2004): Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis., 39, 1407-1416.
10. de Wet, N., Llanos-Cuentas, A., Suleiman, J., et al. (2004): A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis., 39, 842-849.
11. Kuse, E.R., Chetchotisakd, P., da Cunha, C.A., et al. (2007): Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 369, 1519-1527.
12. Pappas, P.G., Rotstein, C.M., Betts, R.F., et al. (2007): Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis., 45, 883-893.
13. Denning, D.W. (2003): Echinocandin antifungal drugs. Lancet, 362, 1142-1151.
14. Nishiyama, Y., Uchida, K. and Yamaguchi, H. (2002): Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J. Electron Microsc., 51, 247-255.
15. Nishiyama, Y., Hasumi, Y., Ueda, K., et al. (2005): Effects of micafungin on the morphology of Aspergillus fumigatus.J. Electron Microsc., 54, 67-77.
16. Baixench, M.T., Aoun, N., Desnos-Ollivier, M., et al. (2007): Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother., 59, 1076-1083.
17. Cleary, J.D., Garcia-Effron, G., Chapman, S.W., et al. (2008): Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother., 52, 2263-2265.
18. Park, S., Kelly, R., Kahn, J.N., et al. (2005): Specific substitutions in the echinocandin target Fks1paccount for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother., 49, 3264-3273.
19. Garcia-Effron, G., Park, S. and Perlin, D.S. (2009): Correlating echinocandin MIC and kinetic inhibition of fksl mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother., 53, 112-122.
20. Katiyar, S., Pfaller, M. and Edlind, T. (2006): Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother., 50, 2892-2894.
21. Krogh-Madsen, M., Arendrup, M.C., Heslet, L., et al. (2006): Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis., 42, 938-944.
22. Thompson, G.R., 3rd., Wiederhold, N.P., Vallor, A.C., et al. (2008): Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother., 52, 3783-3785.
23. Pfeiffer, CD., Garcia-Effron, G., Zaas, A.K., et al. (2010): Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol., 48, 2373-2380.
24. Garcia-Effron, G., Lee, S., Park, S., et al. (2009): Effect of Candida glabrata FKSI and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother., 53, 3690-3699.
25. Garcia-Effron, G., Katiyar, S.K., Park, S., et al. (2008): A naturally occurring proline-to-alanine amino acid change in FksIp in Candida parapsilosis, Candida orthopsilosis,and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother., 52, 2305-2312.
26. Arendrup, M.C., Perkhofer, S., Howard, S.J., et al. (2008): Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother., 52, 3504-3511.
27. Kanbe, T., Horii, T., Arishima, T., et al. (2002): PCR-based identification of pathogenic Candida species using primer mixes specific to Candida DNA topoisomerase II genes. Yeast, 19, 973-989.
28. Clinical and Laboratory Standards Institute (2008): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, Pa.
29. Maki, K., Matsumoto, S., Watabe, E., et al. (2008): Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol. Immunol., 52, 383-391.
30. Ikeda, F., Wakai, Y., Matsumoto, S., et al. (2000): Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother., 44, 614-618.
31. Hatano, K., Morishita, Y., Nakai, T., et al. (2002): Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. (Tokyo), 55, 219-222.
32. Dixon, M. (1953): The determination of enzyme inhibitor constants. Biochem. J., 55, 170-171.
33. Clinical and Laboratory Standards Institute (2008): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, Pa.
34. Niimi, K., Monk, B.C., Hirai, A., et al. (2010): Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSCI (FKSI) allele followed by loss of heterozygosity. J. Antimicrob. Chemother., 65, 842-852.